Plandai Preparing for Strong 2014

Marketwired

BALTIMORE, MD--(Marketwired - Oct 24, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that a series of development milestones and clinical trials scheduled to conclude or commence this quarter and early next year for Plandaí Biotechnology, Inc. (OTCQB: PLPL), will serve as a catalyst for meaningful revenue generation in 2014.

For example, Plandaí is already in the midst of a key, clinical study to determine the absorption level of its Phytofare™ Pheroid™ Topical Catechin Complex when used in topical creams and solutions. Another trial seeks to confirm the anti-inflammatory characteristics and properties inherent in the use of the same product with topical creams to reduce irritation and inflammation. Results of both trials are slated to be released in the early part of 2014.

Other fourth quarter 2013 human trials that should have a direct impact on revenue in 2014 include a 90-subject weight loss trial utilizing the Company's flagship product, and a trial to measure the effectiveness of Phytofare™ Limonoid Glycoside Complex cold and flu treatment.

In early 2014, the Company will launch a trial to test anti-aging properties of its topical cream delivered offering. Solid results from this trial should result in a landmark transaction for the Company with Oasix, Inc., a Canadian company that develops and markets skin care products and also operates the Oasis Skin Institute in Alberta, Canada. Not only would it trigger the balance of an earlier agreed upon total initial payment of $500,000, but due to a 5-year license agreement with Oasix, minimum quantity purchases of the Topical Catechin Complex from Plandaí for use in multiple skin care products, will commence.

With the conclusion of these trials and a new Phytofare human bioavailability study in 1Q14, Plandaí is making the transition from a pure research and development firm to an R&D-based firm that is able to generate meaningful commercial revenue in the key segments of the lucrative nutraceutucal industry. This shift will be clearly evident in the first half of 2014, and will likely be reflected in a rise in market value and the stock price, well ahead of these milestone events.

This press release contains excerpts of our most recently published article on Plandaí. Goldman Small Cap Research sponsored articles, reports, and updates on Plandai as well as associated disclaimers and disclosures can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com
View Comments (0)